ENTPD1 and neoplasm: Kortekaas et al., 2020 (53) observed that a weak response against tumor antigens could be identified in CD39- sorted CD4+ TILs, and tumor-reactive TILs can be found within a CD39- CD69- population in TILs expanded for adoptive T cell therapy (54).